Abstract
Patients with well-differentiated neuroendocrine tumours of the gastrointestinal tract often present with metastases and hormonal symptoms. These patients can be palliated by interventional tumour reduction and medical treatment with somatostatin analogues; no effective chemotherapy is available. Radionuclide therapy via somatostatin receptors is one new therapeutic alternative. The recognition that neuroendocrine tumours express specific receptors for growth factors and chemokines, which are of importance for tumour growth, vascularization, and spread, may open the way for new therapeutic approaches. The signalling pathways in carcinoid tumours are incompletely explored. This review summarizes potential new treatment strategies from clinical and experimental studies, e.g. inhibition of angiogenesis, targeting of growth factors or their receptors by tyrosine kinase inhibitors, interference with specific cellular pathways (mTOR, PI3K, RAS/RAF, Notch), and also inhibition of the proteasome and histone deacetylation. Combining targeted therapy with chemotherapy, or using drugs to sensitize for radionuclide therapy, may enhance the treatment outcome.
Keywords: monoclonal antibody, growth factor receptor, Angiogenesis inhibition, multikinase inhibition, neuroendocrine tumour, radionuclide therapy, small molecule inhibitor, somatostatin receptor
Anti-Cancer Agents in Medicinal Chemistry
Title: New Medical Strategies for Midgut Carcinoids
Volume: 10 Issue: 3
Author(s): Ola Nilsson, Yvonne Arvidsson, Viktor Johanson, Eva Forssell-Aronsson and Hakan Ahlman
Affiliation:
- Department of Surgery, Sahlgrenska University Hospital, SE-413 45 Goteborg, Sweden.,Sweden
Keywords: monoclonal antibody, growth factor receptor, Angiogenesis inhibition, multikinase inhibition, neuroendocrine tumour, radionuclide therapy, small molecule inhibitor, somatostatin receptor
Abstract: Patients with well-differentiated neuroendocrine tumours of the gastrointestinal tract often present with metastases and hormonal symptoms. These patients can be palliated by interventional tumour reduction and medical treatment with somatostatin analogues; no effective chemotherapy is available. Radionuclide therapy via somatostatin receptors is one new therapeutic alternative. The recognition that neuroendocrine tumours express specific receptors for growth factors and chemokines, which are of importance for tumour growth, vascularization, and spread, may open the way for new therapeutic approaches. The signalling pathways in carcinoid tumours are incompletely explored. This review summarizes potential new treatment strategies from clinical and experimental studies, e.g. inhibition of angiogenesis, targeting of growth factors or their receptors by tyrosine kinase inhibitors, interference with specific cellular pathways (mTOR, PI3K, RAS/RAF, Notch), and also inhibition of the proteasome and histone deacetylation. Combining targeted therapy with chemotherapy, or using drugs to sensitize for radionuclide therapy, may enhance the treatment outcome.
Export Options
About this article
Cite this article as:
Nilsson Ola, Arvidsson Yvonne, Johanson Viktor, Forssell-Aronsson Eva and Ahlman Hakan, New Medical Strategies for Midgut Carcinoids, Anti-Cancer Agents in Medicinal Chemistry 2010; 10(3) . https://dx.doi.org/10.2174/1871520611009030250
DOI https://dx.doi.org/10.2174/1871520611009030250 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Peptide-based Radiopharmaceuticals for Targeted Tumor Therapy
Current Medicinal Chemistry The Place of Somatostatin Analogs in the Diagnosis and Treatment of the Neuoroendocrine Glands Tumors
Recent Patents on Anti-Cancer Drug Discovery Towards the Molecular Imaging of Prostate Cancer Biomarkers Using Protein-based MRI Contrast Agents
Current Protein & Peptide Science An Overview of Bioactive Peptides for in vivo Imaging and Therapy in Human Diseases
Mini-Reviews in Medicinal Chemistry Molecular Biotheranostic Approaches of Cancers Using LAT Kit Probes
Current Medical Imaging Targeted Drug Delivery: Trends and Perspectives
Current Drug Delivery Pancreatic Neuroendocrine Tumors: Signal Pathways and Targeted Therapies
Current Molecular Medicine Neuro-endocrine Markers in Neoplasms. Diagnostic Interest and Future Prospects
Current Proteomics The Radionuclide Molecular Imaging and Therapy of Neuroendocrine Tumors
Current Cancer Drug Targets B Cell Modulation Strategies in Autoimmunity: The SLE Example
Current Pharmaceutical Design Pulmonary Neuroendocrine Cell System in Health and Disease
Current Respiratory Medicine Reviews Recent Advances in Half-life Extension Strategies for Therapeutic Peptides and Proteins
Current Pharmaceutical Design Rational Targeting of the Urokinase Receptor (uPAR): Development of Antagonists and Non-Invasive Imaging Probes
Current Drug Targets Radionuclides Used in Nuclear Medicine Therapy – From Production to Dosimetry
Current Medical Imaging Cell Surface Nucleolin as a Target for Anti-Cancer Therapies
Recent Patents on Anti-Cancer Drug Discovery The Epidemiological, Mechanistic and Potential Clinical Role of Androgen Receptor (AR) in Urothelial Carcinoma
Current Drug Targets Radiation Therapy in the Early 21st Century: Technological Advances
Current Cancer Therapy Reviews Imaging of Spinal Bone Tumors: Principles and Practice
Current Medical Imaging Can PET Imaging Facilitate Optimization of Cancer Therapies?
Current Pharmaceutical Design Beta-Emitting Radionuclides for Peptide Receptor Radionuclide Therapy
Current Topics in Medicinal Chemistry